The experimental cancer drug ibrutinib has wowed in clinical trials, beating deadly blood cancers without the painful side effects of currently approved therapies.
And it has raced through development and regulatory hurdles, in part thanks to a US program to accelerate the development of particularly promising drugs, says its developer Pharmacyclics, based in Sunnyvale, California.
The US Food and Drug Administration (FDA) launched the ‘breakthrough therapy’ designation in 2012, and the label has been eagerly embraced by the pharmaceutical industry. Recent months have seen a steady stream of drugs being submitted for review. For some firms — particularly young ones — the designation can bring an extra boost of cash by raising investor confidence.
But for all the fanfare, the industry is also watching closely to see exactly what benefits can be gained by having a drug reviewed through this route. “It’s like winning a beauty pageant,” says Timothy Coté, a former director of the FDA’s Office of Orphan Products Development who now runs a consultancy called Coté Orphan Consulting in Silver Spring, Maryland. “It doesn’t have specific tangible outcomes, but it does appear to have enlivened the community.”
The breakthrough therapy designation was created by the FDA Safety and Innovation Act, a law that requires the agency to fast-track promising drugs for serious or life-threatening conditions. The FDA aims to do this by meeting early and often with developers, as well as working with them to design clinical trials that deliver the needed data quickly and efficiently.
The industry leapt on the opportunity, so far submitting 99 applications for the designation. But the flurry of applications may partly be a product of confusion, says Coté: the FDA has avoided laying out detailed descriptions of what constitutes a breakthrough, and some companies are unsure of the criteria. “Most biotech chief executives with something in the clinic think that they’re already there,” Coté says — but 47 of the applications submitted in the past year have been denied. In most cases the denials are due to insufficient clinical data, the FDA says.
The Latest Bing News on:
Fast-Track Drugs
- Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Runon May 10, 2024 at 10:49 am
Edgewise reveals strong cash position and progressing clinical-stage programs, sparking a bull run. Find out why this is a good time to sell EWTX stock.
- Feds: Man gets 10 years in 'fast-food-style' drug distribution case that left one deadon May 10, 2024 at 3:31 am
In all, seven people were sentenced in federal court in the drug dealing operation in Detroit that federal prosecutors said operated 24-7.
- SN Bioscience Receives FDA Fast Track Designation for Small Cell Lung Canceron May 9, 2024 at 8:59 pm
SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer (SCLC) for SNB-101 (API: SN-38), a new drug for polymer ...
- 7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025on May 9, 2024 at 7:34 am
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors are well aware of the explosive growth potential in weight loss drug ...
- Buy Rating Justified for Avidity Biosciences Amid Strong Drug Candidate Prospects and Regulatory Advancementson May 8, 2024 at 8:17 pm
These developments, coupled with previous Orphan Drug and Fast Track designations, position Avidity Biosciences favorably, thus warranting the Buy rating. Zhu covers the Healthcare sector, focusing on ...
- FDA fast track status granted to iECURE neonatal OTC deficiency treatmenton May 8, 2024 at 6:19 am
T he US Food and Drug Administration (FDA) has granted fast track designation for iECURE’s gene editing therapy, ECUR-506, for the treatment of neonatal onset ornithine transcarbamylase (OTC) ...
- Regulatory Challenges In Drug Approval: Balancing Innovation And Patient Safetyon May 8, 2024 at 5:43 am
Navigating the complex landscape of drug approval presents significant regulatory challenges, requiring a delicate balance between fostering pharmaceutical innovation and ensuring patient safety. The ...
- April 2024 Recap: Drug Pipeline Updateson May 7, 2024 at 5:00 pm
Fast Track designation Datopotamab deruxtecan (AstraZeneca and Daiichi Sankyo) TROP2-directed antibody drug conjugate Treatment of adults with unresectable or metastatic hormone receptor-positive, ...
- Precision BioSciences Gets FDA Fast Track Designation for Program to Treat Genetic Urea Cycle Disorder in Newbornson May 7, 2024 at 6:48 am
Precision BioSciences said Tuesday that its partner, iECURE, has received Fast Track designation from the Food and Drug Administration for ECUR-506. ECUR-506 is iECURE's in vivo gene insertion program ...
- iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiencyon May 7, 2024 at 1:00 am
"The benefits of Fast Track designation may accelerate our ability to get ECUR-506 into physicians’ hands, which is incredibly important when every second counts for these babies." ECUR-506 previously ...
The Latest Google Headlines on:
Fast-Track Drugs
[google_news title=”” keyword=”Fast-Track Drugs” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Breakthrough therapy
- Breakthrough Gene Therapy Enables Infant Born Deaf to Hearon May 10, 2024 at 2:56 pm
Significant hearing improvements have been achieved in an infant with profound hearing loss due to a biallelic otoferlin gene (OTOF) mutation, according to the results of a first-in-human gene therapy ...
- UK toddler regains hearing in gene therapy breakthroughon May 10, 2024 at 12:03 pm
STORY: Banging on blocks and playing the flute, Opal Sandy looks like an average energetic toddler. :: May 1, 2024It would be hard to tell she was born deaf - and unable to hear just months earlier. : ...
- Toddler born deaf can hear after gene therapy trial breakthrough her parents call "mind-blowing"on May 10, 2024 at 8:26 am
The parents of a U.K. toddler say it's "absolutely mind-blowing" to see their daughter, enrolled in a gene therapy trial, hear for the first time.
- Gene therapy brings hearing to baby girl born deafon May 10, 2024 at 7:50 am
Opal Sandy was born into a world she could not hear. The British baby girl, now 18 months old, had a rare genetic condition called auditory neuropathy that interrupted nerve impulses that travel from ...
- Novartis Gets FDA Breakthrough Therapy Designation for Scemblixon May 10, 2024 at 6:29 am
The Swiss pharmaceutical company said the U.S. Food and Drug Administration designated the treatment as a breakthrough therapy for the third time. Drugs that get designated as breakthrough therapies ...
- British baby girl becomes world’s first to regain hearing with gene therapyon May 10, 2024 at 5:57 am
This therapy enabled the baby, who was born with a rare genetic condition that impaired ear function completely, to hear even faint sounds.
- Novartis' Scemblix Gets Breakthrough Designation For Chronic CMLon May 10, 2024 at 3:09 am
(RTTNews) - Novartis AG (NVS) Thursday announced that the FDA has granted Breakthrough Therapy designation to Scemblix for treating adult patients with newly diagnosed Philadelphia chromosome-positive ...
- US FDA grants breakthrough therapy designation to Avidity Biosciences’ delpacibart etedesiran to treat myotonic dystrophy type 1on May 10, 2024 at 1:30 am
US FDA grants breakthrough therapy designation to Avidity Biosciences’ delpacibart etedesiran to treat myotonic dystrophy type 1: San Diego Friday, May 10, 2024, 14:00 Hrs [IST] ...
- Gene therapy breakthrough allows toddler born deaf to hearon May 9, 2024 at 10:03 am
A British toddler born with a genetic condition resulting in deafness can now hear in one ear thanks to a pioneering new gene therapy treatment.
- Sana Biotechnology: Promising Clinical Studies and Breakthrough Potential in T1D Therapyon May 9, 2024 at 3:36 am
In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Sana Biotechnology (SANA – Research Report), ...
The Latest Google Headlines on:
Breakthrough therapy
[google_news title=”” keyword=”breakthrough therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]